Ionis Pharmaceuticals Inc

NASDAQ:IONS  
29.88
-0.13 (-0.43%)
Strategic Combinations, Other Pre-Announcement

AstraZeneca and Ionis Close Agreement To Develop And Commercialise eplontersen

Published: 12/29/2021 07:24 GMT
Ionis Pharmaceuticals Inc (IONS) - Astrazeneca Plc - Astrazeneca and Ionis Close Eplontersen Deal.
Astrazeneca Plc - Astrazeneca and Ionis Close Eplontersen Deal.
Astrazeneca - Under Terms of Agreement, Upfront Payment From Astrazeneca to Ionis is $200m.
Astrazeneca - Astrazeneca Will Make Additional Conditional Payments of Up to $485m Following Regulatory Approvals.
Astrazeneca - It Will Also Pay Up to $2.9bn of Sales-related Milestones Based on Sales Thresholds Between $500m and $6bn.
Astrazeneca - Transaction Does Not Impact Astrazeneca's Financial Guidance for 2021.
Astrazeneca - Collaboration Includes Territory-specific Development, Commercial and Medical Affairs Cost-sharing Provisions.